Sudo Apt Holdings

1 - As I build out open-source interactive games for @scriptkittyorg to be played on @ScriptKittyOS that raise money for the rescues & web apps for rescues, I am also going to be a beta user Meet the Marshmallows @MtMarshmallows

@sama Useless? How so? You are Tony Stark collaborating with Jarvis resulting in fast results. If your only value is feature upgrades then maybe retire & enjoy the life and chaos you've created. Otherwise adapt, overcome & enjoy the ride.

I am very excited about AI, but to go off-script for a minute: I built an app with Codex last week. It was very fun. Then I started asking it for ideas for new features and at least a couple of them were better than I was thinking of. I felt a little useless and it was sad.

@bryan_johnson @drink_AG1 I would never use AG1 because its obvious lack of legitimacy however I would shift the blame on the influencers for being greedy & pushing crap to their loyal fans. AG1 has an obvious great marketing team.

@drink_AG1 Let’s be real. You pay influencers $$$$ to promote. Not because it’s worth $79, but bc you all get rich. Trying to defend a legit science stance is silly. It’s disingenuous to people sincerely trying to improve their health. The health benefits of AG1 are worth $30, max.

I’d cancel your AG1 subscription. They just completed a clinical trial and the results show no clinical benefit.  This has been obvious for years.  AG1 has no real product substance and is fundamentally an influencer heist.   Two simple alternatives (75% and 56% less $), outperform AG1 in randomized clinical trials. Two simple mono-ingredient alternatives that outperform AG1: 1. Chicory inulin 12 g daily ($20/mo) 2. Resistant starch 30 g daily for 12 weeks ($35/mo) AG1 is not worth $79/mo. AG1 study results (4-weeks, N=30): + No significant changes in blood biomarkers compared to placebo (CBC, CMP, lipids). + No statistically significant improvement in digestive quality-of-life scores (p = 0.058). + No significant metabolic or inflammatory biomarker benefits of any kind within the scope of what was measured in the trial. + Only small shifts in microbiome taxa but clinically irrelevant at this stage. + The intervention did not increase microbiome diversity compared to placebo. Alpha diversity was unchanged, and the taxa changes seen were only from pre- to post-analysis within each group. Between-group differences were limited, and the placebo actually showed similar or even potentially larger shifts. This means the observed changes fall within normal placebo-driven variability, not a real treatment effect. No global microbiota shifts were detected. Chicory inulin 12 g in constipation patients + 12 g of chicory inulin daily for 4 weeks (compared to maltodextrin placebo) + Global microbiota shifts: enrichment in butyrate-producing Bifidobacterium and Anaerostipes, and depletion of the pro-inflammatory Bilophila. +The effect was seen by comparing intervention vs placebo in a cross-over setting, a very rigorous type of clinical analysis in which each person serves as their own control, eliminating a lot of individual random noise. + The trial also met its primary objective by improving constipation symptoms in the targeted patient group. Resistant starch daily 30g for 12 weeks in older adults + Significant increase in Bifidobacterium in both middle-aged and elderly participants, with an increase in the beneficial microbiome byproduct butyrate, and reductions in Proteobacteria (including inflammatory Escherichia–Shigella) in the elderly. + Resistant starch also significantly reduced blood glucose, and produced greater reductions in blood insulin and insulin resistance (HOMA-IR) in the elderly group.

@TheDrMAWZ Is this going to be trial'd for Parkinsons?

This represents a fundamental shift in neurology: From: "How do we suppress abnormal brain activity?" (seizure-focused) To: "How do we enhance healthy brain states?" (REM-focused, neuroprotective) BMB-101 is the first drug bridging that gap. Full data: Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

A new drug in the middle of clinical trials just increased REM sleep by 90% without making people sleep longer! This is the first medication ever to specifically enhance REM only and the implications go far beyond seizure control. Here's what just happened. 🧵

@ProtonMail ████████ ████████ ████████ ████████ ████████ ████████ ████████ █

████████ Google ███ ███████████ would never ███████████ ████████ ████████ ████████ ████████ violate ████████ ████████ ████████ ████████ your ████████ privacy ██████

Site is live

Okie... sudoapt.holdings is now live & there is a mini ctf in the site for those that can't help themselves. It was quickly coded today so be nice. Project links don't work yet but icons are there as placeholders. One step at a time. Next is the non-profit site

The 1st IP my holdings company @sudoaptholdings owns is an AI Red Teaming game I designed. I hired a game developer company to build it & it will live on @ScriptKittyOS on the hacker mode side. Shits getting real.